Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus

Diabetic Medicine

Volumn 17, Issue 4, 2000, Pages 287-294

  Nolan, John J ^a   Jones, N P ^b   Patwardhan, R ^b   Deacon, L F ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Fasting plasma glucose; Peroxisomal proliferator activated receptor (PPAR ); Rosiglitazone; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

ROSIGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FRUCTOSAMINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PLACEBOS; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 0034105713     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00269.x     Document Type: Article

References (25)

1. 1 Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997; 14: S1-S85.
2. 2 De Fronzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-873.
3. 3 Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
4. 4 Groop LC. Sulphonylureas in NIDDM. Diabetes Care 1992; 15: 737-754.
5. 5 Inzucchi SE, Maggs DG, Spollett G, Page SL, Rife FS, Walton V et al. Efficacy and metabolic effects of metformin and troglitazone in Type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
6. 6 Lebovitz HE. α-Glucosidose inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-145.
7. 7 Henry RR. Thiazolidinediones. Endocrinol Met Clinics North Am 1997; 26: 553-573.
8. 8 Saltiel A, Olefsky J. Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes 1996; 45: 1661-1669.
9. 9 Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 1998; 83: 3169-3176.
10. 10 Smith SA, Cawthorne MA, Coyle PJ, Holder JC, Kirkham DM, Lister CA et al. BRL 49653 normalises glycaemic control on Zucker falfa rats by improving hepatic and peripheral tissue sensitivity to insulin. Diabetologia 1993; 36: A184. (Abstract).
11. 11 Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ et al. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes 1995; 44: 1087-1092.
12. 12 Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K et al. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995; 38: 24-30.
13. 13 Smith S, Boam D, Cawthorne MJ, Sidaway M, Newman M, Wilkinson et al. Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNA in hypertrophied pancreatic islets. Diabetologia 1998; 41: 659. (Abstract).
14. 14 Patel J, Miller R, Hu J. BRL 49653 (a thiazolidinedione) improves glycemic control in NIDDM patients. Diabetes 1997; 46: 150A. (Abstract).
15. 15 National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
16. 16 Williams DA. The comparison of several dose levels with a zero dose control. Biometrics 1972; 28: 519-531.
17. 17 Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem 1995; 270: 12953-12956.
18. 18 Patel J, Miller E, Patwardhan R, Rosiglitazone 011 Study Group. Rosiglitazone has significant glucose lowering effect in type 2 diabetic patients. Diabetes 1998; 47: A17. (Abstract).
19. 19 Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 1997; 183: 173-183.
20. 20 Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 1998; 41: 35-43.
21. 21 Anonymous. Troglitazone liver injury. WHO Drug Information 1998; 12: 13.
22. 22 Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal prolifcrator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-759.
23. 23 Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. Eur J Clin Pharmacol 1998; 54: 567-571.
24. 24 Spencer CM, Markham A. Troglitazone. Drugs 1997; 54: 89-101.
25. 25 Elcock FJ, Lyon JJ, Hitchcock J, Morgan DG, Bertram TA, Bugelski PJ. Toxicity of troglitazone in cultured rat hepatocytes. Diabetes 1999; 48: A63. (Abstract).